Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARO-RAGE Injection
ARO-RAGE · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-RAGE | EXPERIMENTAL | ARO-RAGE inhalation |
| Placebo | PLACEBO_COMPARATOR | Normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-RAGE | DRUG | Inhalation of nebulized solution |
| Placebo | DRUG | Calculated volume to match active treatment by inhalation of nebulized solution |
| ARO-RAGE Injection | DRUG | ARO-RAGE injection for sc administration |
Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to us...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
ARO-RAGE is an investigational medicine being developed for the treatment of asthma, a respiratory condition. It is administered as an inhaled therapy and is currently in Phase 2 clinical development. It has not been approved for commercial use, and its safety and efficacy in asthma are still being evaluated in clinical trials.
ARO-RAGE targets RAGE, the receptor for advanced glycation end products. By targeting this receptor in the lung, the therapy is designed to reduce RAGE-mediated inflammatory signaling associated with asthma. RAGE is the molecular target named for this inhaled investigational candidate, which is being studied in allergen-induced mild asthma.
ARO-RAGE is being developed by Arrowhead Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ARWR. The company is the sponsor of the clinical program evaluating the inhaled candidate in asthma. Arrowhead Pharmaceuticals is responsible for the ongoing Phase 2 study and the completed Phase 1 studies of ARO-RAGE.
ARO-RAGE is in Phase 2 clinical development for asthma. It is an investigational therapy and has not been approved by the FDA or any other regulatory authority. Two earlier Phase 1 studies have been completed, and a Phase 2 study in allergen-induced mild asthma is currently recruiting participants.
ARO-RAGE has been studied in three clinical trials. The recruiting Phase 2 trial is NCT07241546, a study of inhaled ARO-RAGE in allergen-induced mild asthma. Completed Phase 1 trials include NCT05533294 in healthy subjects and NCT05276570 in healthy subjects and patients with inflammatory lung disease. Total enrollment across these trials is 206 participants.
ARO-RAGE Injection is another name used for ARO-RAGE, the investigational asthma therapy developed by Arrowhead Pharmaceuticals. Both names refer to the same candidate, which targets RAGE and is being evaluated in Phase 2 clinical development. Searches for either name point to the same drug program.